Search the MBS

Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician, to determine:

1. if requirements relating to ALK gene rearrangement status for access to an anaplastic lymphoma kinase inhibitor under the Pharmaceutical Benefits Scheme are fulfilled; or
2. if requirements relating to ALK status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00

• Previous - Item 73340
• Next - Item 73342